Praxis Precision Medicines

PRAXPhase 3

Praxis Precision Medicines (NASDAQ: PRAX) is a clinical-stage biotech company revolutionizing CNS drug development through genetics-based approaches. The company has built a comprehensive pipeline targeting rare epilepsies and neurological disorders, with multiple Phase 2/3 studies currently ongoing including the RESILIENCE and ENERGY programs. Their precision medicine approach focuses on therapeutic targets identified through human genetics, utilizing translational tools and patient-guided development strategies.

Market Cap

$8.3B

Employees

100-250

Focus

Small Molecules

PRAX · Stock Price

USD 298.31+131.96 (+79.33%)

Historical price data

AI Company Overview

Technology Platform

Genetics-first precision medicine platform that translates insights from genetic epilepsies into therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. The platform utilizes human genetics to identify therapeutic targets and employs translational tools for target validation.

Pipeline Snapshot

15 drugs in pipeline, 7 in Phase 3

Drug	Indication	Stage
1mg elsunersen + 0.5mg elsunersen	Epileptic Encephalopathy	Phase 3
vormatrogine	Epilepsy, Tonic-Clonic	Phase 3
1.0mg/kg/day PRAX-562 + 1.5mg/kg/day PRAX-562 + Placebo	Developmental and Epileptic Encephalopathy 1	Phase 3
60 mg ulixacaltamide + Placebo	Essential Tremor	Phase 3
20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks + Pla...	Focal Seizure	Phase 2/3

Opportunities

Multiple late-stage clinical programs provide near-term value catalysts, with the genetics-first precision medicine approach positioning the company to capitalize on the growing trend toward personalized CNS therapeutics.

The underserved rare epilepsy markets offer significant commercial potential with favorable regulatory pathways.

Risk Factors

Clinical development risks in the challenging CNS therapeutic area, complex regulatory pathways for rare pediatric epilepsies, and competitive pressures from well-funded competitors and potential large pharma entrants.

The company's pre-revenue status creates dependency on successful clinical outcomes for continued funding.

Competitive Landscape

Competes with specialized CNS companies like Marinus Pharmaceuticals and Ovid Therapeutics, while differentiating through genetics-first precision medicine approach. Recent acquisitions in the space (Zogenix by UCB, GW Pharma by Jazz) demonstrate strategic interest from larger pharmaceutical companies in innovative CNS assets.

Publications

Patents

Pipeline